Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1991
The disposition and metabolism of [14C]piritrexim in dogs after intravenous and oral administrationJ L Woolley, D V Deangelis, M E Grace, et al.
The Journal of Urology|September 1, 1986
Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinomaB H Lau, J L Woolley, C L Marsh, et al.
Pharmaceutical Research|September 1, 1999
Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitorJ W Polli, J L Jarrett, S D Studenberg, et al.
Journal of Neurosurgery|February 1, 1994
Cognitive functioning in long-term survivors of high-grade gliomaY M Archibald, D Lunn, L A Ruttan, et al.
Antimicrobial Agents and Chemotherapy|September 1, 1990
Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditisM L Grayson, C Thauvin-Eliopoulos, G M Eliopoulos, et al.
Critical Care Medicine|January 1, 1988
Effect of the calcium entry blocker verapamil on renal ischemiaJ L Woolley, G R Barker, W K Jacobsen, et al.
The Journal of Infectious Diseases|April 16, 1998
Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumoniaW T Hughes, E M Sillos, S LaFon, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1989
A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U)G R Weiss, G A Sarosy, T D Shenkenberg, et al.
Journal of Clinical Pharmacology|April 18, 2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjectsB M Sadler, G E Chittick, R E Polk, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductaseC W Sigel, A W Macklin, J L Woolley, et al.
Pageof 5